bluuebunny/crossref_metadata_2025_split huggingface dataset:
ZNF804A and schizophrenia susceptibility in Asian populations
Authors: Li Ming , Shi Cui‐Juan , Shi Yong‐Yong , Luo Xiong‐Jian , Zheng Xue‐Bin , Li Zhi‐Qiang , Liu Jian‐Jun , Chong Siow‐Ann , Lee Jimmy , Wang Yi , Liu Xing‐Yan , Yin Li‐De , Pu Xing‐Fu , Diao Hong‐Bo , Xu Qi , Su Bing 
Published: August 2012

AbstractZNF804A, a recently identified risk gene for schizophrenia, has been extensively investigated and the principle finding for this locus has been the association with SNP rs1344706 in populations of European ancestries. However, in Asian populations, only a few studies have been conducted for rs1344706 and the results were inconsistent. Here, we studied rs1344706 and schizophrenia susceptibility in multiple Asian case–control samples (10 Chinese and 2 Japanese samples; N = 21,062), and the meta‐analyses indicated non‐significant association of rs1344706 with schizophrenia (P = 0.26), suggesting the same SNP identified in European samples is not predisposing risk in Asians. Further genotyping and association analyses of a set of SNPs spanning the entire genomic region of ZNF804A (520 kb) identified no association except for SNP rs359895 (P = 7.8 × 10−5, N = 5,172), a newly reported risk SNP located in the ZNF804A promoter region with functional implications. This suggests that ZNF804A may also contribute to schizophrenia susceptibility in Asians although the risk SNP is different from that in Europeans, and it was supported by the detected up‐regulation of ZNF804A mRNA expression in the blood cells of Chinese schizophrenia patients compared with normal controls (P = 0.004). Additionally, the linkage disequilibrium (LD) structure analyses using data from HapMap indicated distinct LD blocks across ZNF804A between Chinese and Europeans, which may explain the different association patterns between them, and also highlight the compounding difficulty of genetic studies of complex diseases like schizophrenia when studying multiple ethnic populations. © 2012 Wiley Periodicals, Inc.
The mitochondrial genome and psychiatric illness
Authors: Anglin Rebecca E.S. , Mazurek Michael F. , Tarnopolsky Mark A. , Rosebush Patricia I. 
Published: August 2012

AbstractPsychiatric disorders are a leading cause of morbidity and mortality, yet their underlying pathophysiology remains unclear. Searches for a genetic cause of bipolar disorder, schizophrenia, and major depressive disorder have yielded inconclusive results. There is increasing interest in the possibility that defects in the mitochondrial genome may play an important role in psychiatric illness. We undertook a review of the literature investigating mitochondria and adult psychiatric disorders. MEDLINE, PsycINFO, and EMBASE were searched from their inception through September 2011, and the reference lists of identified articles were reviewed for additional studies. While multiple lines of evidence, including clinical, genetic, ultrastructural, and biochemical studies, support the involvement of mitochondria in the pathophysiology of psychiatric illness, many studies have methodological limitations and their findings have not been replicated. Clinical studies suggest that psychiatric features can be prominent, and the presenting features of mitochondrial disorders. There is limited but inconsistent evidence for the involvement of mitochondrial DNA haplogroups and mitochondria‐related nuclear gene polymorphisms, and for mitochondrial ultrastructural and biochemical abnormalities in psychiatric illness. The current literature suggests that mitochondrial dysfunction and mitochondrial genetic variations may play an important role in psychiatric disorders, but additional methodologically rigorous and adequately powered studies are needed before definitive conclusions can be drawn. © 2012 Wiley Periodicals, Inc.
New clay‐supported Ziegler–Natta catalyst for preparation of PE/Clay nanocomposites via in situ polymerization
Authors: Abedi Sadegh , Abdouss Majid , Nekoomanesh‐Haghighi Mehdi , Sharifi‐Sanjani Naser 
Published: August 2012

AbstractPolyethylene/clay (PE/Clay) nanocomposites were prepared by the in situ polymerization of ethylene using the new Clay/butyl octyl magnesium (BOM)/Chloroform/EtOH/TiCl4/tri ethyl aluminum (TEA) catalyst system in heptane where BOM and TEA were the support for the clay modification and cocatalyst, respectively. The influence of the modified clay using BOM on the catalyst and polymerization was investigated. Also, the effect of temperature, pressure, hydrogen, and the molar ratios of TEA/Ti on the catalyst yield and ethylene consumption (polymerization rate) were studied. It was found that the above clay‐supported catalyst was an efficient Ziegler–Natta type catalyst due to its suitable yield for the polymerization of ethylene toward the production of the PE/Clay nanocomposites. © 2012 Wiley Periodicals, Inc. J. Appl. Polym. Sci., 2013
Temperature dependence of fracture behavior of PA6/OMMT nanocomposites
Authors: Monami A. , Reincke K. , Grellmann W. , Kretzschmar B. 
Published: August 2012

AbstractThe aim of this work was to characterize the fracture behavior of polyamide 6 (PA6) and PA6 reinforced with clay (organically modified montmorillonite) [PA6/OMMT] at different temperatures and under higher loading rate. Pure PA6 and PA6 with different amounts and two types of OMMT were investigated. The structure and morphology of the nanocomposites were analyzed by X‐ray diffraction technique and transmission electron microscopy. The fracture behavior was evaluated using the instrumented Charpy impact test at different temperatures starting from −30 °C up to 50 °C. To determine the fracture toughness KId at higher temperatures, the equivalent‐energy concept was used. Based on the J‐value versus temperature diagrams, the brittle‐to‐tough transition temperature TBTT of the materials was determined. It was found that the crack toughness as a function of temperature and the TBTT are influenced by the content of OMMT and the morphology. There are indications that at low OMMT contents, the deformation behavior is dominated by the matrix properties. With increasing filler content, the influence of the nanostructure on TBTT increases. The crack toughness of the nanocomposites with an intercalated morphology is higher than that of exfoliated ones, due to additional energy‐dissipating mechanisms. © 2012 Wiley Periodicals, Inc. J. Appl. Polym. Sci, 2013
Plasma polymerization‐modified bacterial polyhydroxybutyrate nanofibrillar scaffolds
Authors: Karahaliloğlu Zeynep , Demirbilek Murat , Şam Mesut , Erol‐Demirbilek Melike , Sağlam Necdet , Denkbaş Emir Baki 
Published: August 2012

AbstractThe design and the development of novel scaffold materials for tissue engineering have attracted much interest in recent years. Especially, the prepared nanofibrillar scaffold materials from biocompatible and biodegradable polymers by electrospinning are promising materials to be used in biomedical applications. In this study, we propose to produce low‐cost and cell‐friendly bacterial electrospun PHB polymeric scaffolds by using Alcaligenes eutrophus DSM 545 strain to PHB production. The produced PHB was characterized by Nuclear Magnetic Resonance (NMR) and Fourier Transform Infrared Spectroscopy (FTIR). Nanofibrous scaffolds were fabricated via electrospinning method that has a fiber diameter approximately 700–800 nm. To investigate cell attachment, cell growth, and antioxidant enzyme activity on positively and negatively charged PHB scaffold, PHB surface was modified by plasma polymerization technique using polyethylene glycol (PEG) and ethylenediamine (EDA). According to the results of superoxide dismutase (SOD) activity study, PEG‐modified nanofibrillar scaffolds indicated more cellular resistance against oxidative stress compared to the EDA modification. As can be seen in cell proliferation results, EDA modification enhanced the cell proliferation more than PEG modification, while PEG modification is better as compared with nonmodified scaffolds. In general, through plasma polymerization technique, surface modified nanofibrillar structures are effective substrates for cell attachment and outgrowth. © 2012 Wiley Periodicals, Inc. J. Appl. Polym. Sci., 2013
Solidification behavior of high‐density polyethylene during injection molding process: Enthalpy transformation method
Authors: Yang Bin , Miao Ji‐Bin , Min Kai , Xia Ru , Qian Jia‐Sheng , Wang Xing 
Published: August 2012

AbstractIt was widely established that many end‐use properties of the final parts are considerably affected by the macromolecular hierarchical structures formed during the cooling stage of injection molding, especially for crystalline polymers which undergo both solidification and crystallization processes simultaneously. Enthalpy transformation method (ETM) has been demonstrated to give the reasonable descriptions of the temperature profiles for real processing operations (e.g., injection molding, gas‐assisted injection molding, and compression molding, etc.) in our previous work. However, to observe the phase‐change plateau, where rapid cooling rate is imposed, is not easy in traditional treatments using the enthalpy approach. In this work, “modified cooling curves” (i.e., temperature versus time, plotted in logarithmic scale) at various locations in the mold cavity were found to show similar trend with an obvious turning point indicating the occurrence of phase transition. Mold temperature is more effective in controlling the cooling rate than melt temperature. Turing point of the cooling curves in the plot of ln θ vs. ln t can be used to estimate the minimum cooling time of the injection molding of crystalline polymers. © 2012 Wiley Periodicals, Inc. J. Appl. Polym. Sci., 2013
The emerging biology of muscle stem cells: Implications for cell‐based therapies
Authors: Bentzinger C. Florian , Wang Yu Xin , von Maltzahn Julia , Rudnicki Michael A. 
Published: August 2012

AbstractCell‐based therapies for degenerative diseases of the musculature remain on the verge of feasibility. Myogenic cells are relatively abundant, accessible, and typically harbor significant proliferative potential ex vivo. However, their use for therapeutic intervention is limited due to several critical aspects of their complex biology. Recent insights based on mouse models have advanced our understanding of the molecular mechanisms controlling the function of myogenic progenitors significantly. Moreover, the discovery of atypical myogenic cell types with the ability to cross the blood‐muscle barrier has opened exciting new therapeutic avenues. In this paper, we outline the major problems that are currently associated with the manipulation of myogenic cells and discuss promising strategies to overcome these obstacles.
Quantifying your body: A how‐to guide from a systems biology perspective
Authors: Smarr Larry 
Published: August 2012

AbstractDuring the coming decade we will see an accelerated digital transformation of healthcare. Leading this change within the institutional medical community are both the move to digital medical records and the use of digital biomedical measurement devices. In addition to this institutional evolution, there is a non‐institutional, bottom‐up, unorganized, highly idiosyncratic movement by early adopters to “quantify” their own bodies. In this article, I share my decade‐long personal experience of tracking many blood and stool biomarkers, which provide insight into the health or disease of major subsystems of my body. These results are interpreted in the context of the genetics of my human DNA and that of the microbes in my gut. Even though I am a computer scientist and not a medical professional, by using commercially available tests and a systems biology integrative approach, I have become an early example of Leroy Hood's vision of the emergence of predictive, preventive, personalized, and participatory (P4) medicine. It is an individual's story illustrating how each of us can contribute to realizing this paradigm shift.
Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib
Authors: Birch M. , Morgan P. E. , Handley S. , Ho A. , Ireland R. , Flanagan R. J. 
Published: August 2012

ABSTRACTA simple HPLC method has been developed to measure imatinib and N‐desmethylimatinib (norimatinib) in plasma or serum at concentrations attained during therapy. Adaptation of this method to LC‐MS/MS also allows dasatinib assay. A small sample volume (100 μL HPLC‐UV, 50 μL LC‐MS/MS) is required and analysis time is <5 min in each case. Detection was by UV (270 nm) or selective reaction monitoring (two transitions per analyte) tandem mass spectrometry. Assay calibration was linear (0.05–10 mg/L imatinib, 0.01–2.0 mg/L norimatinib and 1–200 µg/L dasatinib), with acceptable accuracy (86–114%) and precision (<14% RSD) for both methods. A comparison between whole blood and plasma confirmed that plasma is the preferred sample for imatinib and norimatinib assay. For dasatinib, although whole blood concentrations were slightly higher, plasma is still the preferred sample. Despite considerable variation in the (median, range) plasma imatinib and norimatinib concentrations in patient samples [1.66 (0.02–4.96) and 0.32 (0.01–0.99) mg/L, respectively, N = 104], plasma imatinib was >1 mg/L (suggested target for response) in all but one sample from patients achieving complete molecular response. As to dasatinib, the median (range) plasma dasatinib concentration was 13 (2‐143) µg/L (N = 33). More observations are needed to properly assess the potential role of therapeutic drug monitoring in guiding treatment with dasatinib. Copyright © 2012 John Wiley & Sons, Ltd.
LC‐MS/MS‐ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats
Authors: Sharma Kuldeep , Pawar Gopal , Yadam Swetha , Giri Sanjeev , Rajagopal Sriram , Mullangi Ramesh 
Published: August 2012

ABSTRACTA highly sensitive and specific LC‐MS/MS‐ESI method has been developed for simultaneous quantification of metformin (MFN) and repaglinide (RGN) in rat plasma (50 μL) using phenacetin as an internal standard (IS). Simple protein precipitation was used to extract MFN and RGN from rat plasma. The chromatographic resolution of MFN, RGN and IS was achieved with a mobile phase consisting of 0.2% formic acid in water–acetonitrile (1:1, v/v) with a time program flow gradient on a Chromolith RP‐18e column. The total chromatographic run time was 3.5 min and the elution of MFN, RGN and IS occurred at 1.64, 2.21 and 2.15 min, respectively. A linear response function was established for the range of concentrations 0.855–394 and 0.021–21.7 ng/mL for MFN and RGN, respectively. The intra‐ and inter‐day precision values for MFN and RGN met the acceptance as per FDA guidelines. MFN and RGN were stable in battery of stability studies viz., bench‐top, auto‐sampler and freeze–thaw cycles. The developed assay was applied to a pharmacokinetic study in rats. Copyright © 2012 John Wiley & Sons, Ltd.
Dose‐dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin‐like growth factor‐1
Authors: Nogueira Leticia M. , Lavigne Jackie A. , Chandramouli Gadisetti V. R. , Lui Huaitian , Barrett J. Carl , Hursting Stephen D. 
Published: August 2012

AbstractThe prevalence of obesity, an established risk and progression factor for breast and many other cancer types, remains very high in the United States and throughout the world. Calorie restriction (CR), a reduced‐calorie dietary regimen typically involving a 20–40% reduction in calorie consumption, prevents or reverses obesity, and inhibits mammary and other types of cancer in multiple tumor model systems. Unfortunately, the mechanisms underlying the tumor inhibitory effects of CR are poorly understood, and a better understanding of these mechanisms may lead to new intervention targets and strategies for preventing or controlling cancer. We have previously shown that the anticancer effects of CR are associated with decreased systemic levels of insulin‐like growth factor‐1 (IGF‐1), the primary source of which is liver. We have also reported that CR strongly suppresses tumor development and growth in multiple mammary cancer models. To identify CR‐responsive genes and pathways, and to further characterize the role of IGF‐1 as a mediator of the anticancer effects of CR, we assessed hepatic and mammary gland gene expression, hormone levels and growth of orthotopically transplanted mammary tumors in control and CR mice with and without exogenous IGF‐1. C57BL/6 mice were fed either control AIN‐76A diet ad libitum (AL), subjected to 20%, 30%, or 40% CR plus placebo timed‐release pellets, or subjected to 30% or 40% CR plus timed‐release pellets delivering murine IGF‐1 (mIGF‐1, 20 μg/day). Compared with AL‐fed controls, body weights were decreased 14.3% in the 20% CR group, 18.5% in the 30% CR group, and 38% in the 40% CR group; IGF‐1 infusion had no effect on body weight. Hepatic transcriptome analyses indicated that compared with 20% CR, 30% CR significantly modulated more than twice the number of genes and 40% CR more than seven times the number of genes. Many of the genes specific to the 40% CR regimen were hepatic stress‐related and/or DNA damage‐related genes. Exogenous IGF‐1 rescued the hepatic expression of several metabolic genes and pathways affected by CR. Exogenous IGF‐1 also rescued the expression of several metabolism‐ and cancer‐related genes affected by CR in the mammary gland. Furthermore, exogenous IGF‐1 partially reversed the mammary tumor inhibitory effects of 30% CR. We conclude that several genes and pathways, particularly those associated with macronutrient and steroid hormone metabolism, are associated with the anticancer effects of CR, and that reduced IGF‐1 levels can account, at least in part, for many of the effects of CR on gene expression and mammary tumor burden.
Intravascular ultrasound complements the diagnostic capability of carbon dioxide digital subtraction angiography for patients with allergies to iodinated contrast medium
Authors: Kusuyama Takanori , Iida Hidetaka , Mitsui Hideya 
Published: August 2012

AbstractCarbon dioxide digital subtraction angiography (CO2 DSA) is a useful and safe alternative for patients with renal dysfunction or allergies to iodinated contrast medium. However, CO2 DSA image quality is worse than that of angiography with iodinated contrast medium, primarily because of movement during imaging and stent struts. In angioplasty of arteries of the lower extremities, CO2 DSA cannot be used to sufficiently evaluate target lesions and determine the most efficient intervention. However, in the current case report, we describe a patient with severe allergies to iodinated contrast medium (Stevens–Johnson syndrome), because of which we were unable to use any iodinated contrast medium when conducting angioplasty. Therefore, we used intravascular ultrasound (IVUS), which facilitated the complete observation of the target lesion after stent implantation without requiring iodinated contrast medium. In this case, IVUS was used to complement the diagnostic capabilities of CO2 DSA. © 2012 Wiley Periodicals, Inc.
Impact of target vessel on long‐term survival after percutaneous coronary intervention for chronic total occlusions
Authors: Claessen Bimmer E. , Dangas George D. , Godino Cosmo , Henriques José P.S. , Leon Martin B. , Park Seung‐Jung , Stone Gregg W. , Moses Jeffrey W. , Colombo Antonio , Mehran Roxana ,   Multinational CTO Registry
Published: August 2012

BackgroundThis study sought to investigate whether there is a differential prognostic effect of successful percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) according to the target vessel the CTO is located in.MethodsBetween 1998 and 2007, a total of 1,791 patients underwent PCI of a CTO at three tertiary care centers in the US, Italy, and South Korea. Patients with CTOs in multiple target vessels or the left main stem were excluded (n = 57). Of the remaining 1,734 patients, 609 had a CTO in the left anterior descending (LAD, 35.1%), 391 in the left circumflex (LCX, 22.5%), and 734 in the right coronary artery (RCA, 42.3%). Five‐year mortality and the need for coronary artery bypass grafting (CABG) were compared between patients with successful vs. unsuccessful PCI stratified by target vessel.ResultsProcedural success was obtained in 71.1% of LAD patients, 69.1% of LCX patients, and 65.1% of RCA patients (P = 0.06). The mean follow‐up duration was 1,178 days. Kaplan–Meier estimates of long‐term mortality were 6.7% vs. 11.0% (P = 0.03), 5.5% vs. 13.9% (P < 0.01), and 6.6% vs. 4.1% (P = 0.80) in successful vs. unsuccessful LAD, LCX, and RCA patients, respectively. After multivariate analysis, successful CTO PCI remained associated with lower mortality in the LAD (HR 0.41, P = 0.02) and LCX groups (HR 0.32, P < 0.01). The need for CABG was lower after successful CTO PCI in all three groups (LAD 4.6% vs. 16.0%, P < 0.01; LCX 2.9% vs. 18.2%, P < 0.01, RCA 2.3% vs. 8.4%, P < 0.01).ConclusionThe results from this large contemporary cohort of patients suggest that successful PCI of a CTO in the LAD and the LCX, but not the RCA, is associated with improved long‐term survival. © 2013 Wiley Periodicals, Inc.
Residual mitral valve regurgitation after percutaneous mitral valve repair with the mitraclip® system is a risk factor for adverse one‐year outcome
Authors: Paranskaya Liliya , D'Ancona Giuseppe , Bozdag‐Turan Ilkay , Akin Ibrahim , Kische Stephan , Turan Gökmen R. , Rehders Tim , Ortak Jasmin , Nienaber Christoph A. , Ince Hüseyin 
Published: August 2012

ObjectivesWe undertook this study to investigate the mid‐term clinical results after MitraClip® implantation and the impact of post‐repair mitral valve (MV) function and anatomy on survival and outcome composite endpoint in high‐risk patients.BackgroundPercutaneous MV repair is a potential treatment option for high‐risk patients with severe mitral regurgitation (MR).MethodsMitraClip® was implanted in patients with symptomatic MR rejected to conventional surgery. Differences between patients that survived at follow‐up and patients deceased were tested. A stepwise Cox multivariate analysis was performed to identify independent predictors for composite endpoint of mortality, cardiac re‐hospitalization, re‐intervention, and major cerebro‐vascular and cardiac events.ResultsA total of 85 consecutive patients [78 ± 6 years, 48 (56.5%) men] with severe MR were included. There was no operative mortality while in‐hospital mortality was 3.5% (n = 3) and 30‐day mortality 4.7% (n = 4). Follow‐up was 211 ± 173 days. Survival and composite endpoint‐free survival at one year were 71% and 55%. Multivariate analysis revealed that residual MR immediately after MitraClip® placement (OR 7.4; 95% CI 2.3–23.7) and preoperative MV gradient (OR 2.7; 95% CI 1.5–5.0) were predictors for composite endpoint. Chronic obstructive pulmonary disease (OR 8.3; 95% CI 1.9–37.1) was an additional predictor for composite endpoint.ConclusionMitraClip® is a valid tool with favorable outcomes in high‐risk patients. The degree of residual MR seems to impact on follow‐up composite endpoint outcome. An optimal correction of MR after MitraClip placement could be advocated to optimize the benefits of the procedure and minimize the risk of adverse outcomes. © 2012 Wiley Periodicals, Inc.